profit from every $100 of sales.
$0$100
Connect Biopharma Holdings
$0.68+1.79% today
-59.7% in 1 year
1-year low $0.671-year high $3.69
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Connect Biopharma Holdings sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $64,000 in 2025, with -$55.5 million of profit last year.
SalesProfit
Connect Biopharma Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Connect Biopharma Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Connect Biopharma Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 26 | 0 | |
| – | – | – | – | |
| -117 | -69 | -22 | -58 | |
| -117 | -68 | -22 | -57 | |
| -118 | -62 | -16 | -55 | |
| -2.10 | -1.13 | -0.28 | -1.00 | |
| – | – | – | – | |
| – | – | -86.2% | -90,740.6% | |
| – | – | -60.0% | -86,687.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 174 | 127 | 101 | 56 |
| Cash | 79 | 106 | 78 | 38 |
| Total debt | 0 | 0 | 0 | 1 |
| Total liabilities | 17 | 26 | 9 | 14 |
| 157 | 101 | 92 | 42 | |
| 55 | 55 | 55 | 56 | |
| -58.9% | -53.5% | -19.2% | -107.5% | |
| -75.0% | -61.2% | -17.0% | -132.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -102 | -48 | -24 | -51 | |
| 4 | 0 | 1 | 0 | |
| -106 | -48 | -24 | -52 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 7 | 5 | 7 | 4 |
Valuation
- –
- –
- –
- 3.1×
- 666.3×
- –
- –
- -121.1%
- -130.1%
- 0.0%
Profitability
- 100.0%
- -90,740.6%
- -86,687.5%
- -59,579.2%
- -67.7%
- -71.4%
- -49.4%
- -49.9%
- -68.2%
- 41,781.3%
Growth
- −99.8%
- –
- −112.0%
- –
- +1.6%
Financial health
- -0.7×
- 0.02
- 1.2%
- –
- 3.74
- 3.74
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 946
Bottom 1%of 867
What analysts expect
- Average price target
- $9.00
- Range
- $9.00 – $9.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.34 | -0.29 | −17.2% |
| Mar 31, 2026 | -0.27 | -0.30 | +10.0% |
| Aug 13, 2025 | -0.23 | -0.22 | −4.5% |
| Mar 31, 2025 | -0.06 | -0.27 | +78.7% |
| Sep 5, 2024 | 0.02 | -0.03 | +167.5% |
| Apr 16, 2024 | -0.07 | -0.03 | −131.7% |
| Sep 12, 2023 | -0.08 | -6.92 | +98.9% |
| Apr 11, 2023 | -0.15 | -3.58 | +95.8% |
News
OneMeta Expands VerbumCall to Amazon Connect, Targeting Q1 2027 ReadinessYahoo Finance · Sep 29, 2026Muse AI Makes Meta Connect a Must Watch for InvestorsYahoo Finance · Sep 23, 2026The newest story we have is from Sep 29, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/6Passes 2 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
49No pass
Benjamin Graham
45No pass
Philip Fisher
60Pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
60Pass
Terry Smith
56No pass
Questions about Connect Biopharma Holdings
Is Connect Biopharma Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Connect Biopharma Holdings AI analysis
What does Connect Biopharma Holdings do?
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. It is in Biotechnology.
Does Connect Biopharma Holdings pay a dividend?
No. Connect Biopharma Holdings does not pay a dividend at the moment.
Is Connect Biopharma Holdings stock halal?
No. Connect Biopharma Holdings does not pass our halal screen: its cash and confirmed interest-bearing investments are 90% of its market value, at or above the 33% limit. How we check
How has Connect Biopharma Holdings stock done over the past year?
Down 59.7% over the past twelve months, to $0.68. It traded between $0.67 and $3.69 and is 81.6% below its high.
Who are Connect Biopharma Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Connect Biopharma Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.